logo-loader

Faron Pharmaceuticals Ltd

Receive alerts
Market:
AIM
Market Cap:
£51.16 m
Price
130.00 GBX
Change
-5.11%
52 weeks high
167.97
52 weeks low
50.04

In brief

Faron is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline focusing on acute organ traumas, vascular damage and cancer immunotherapy.

Deep dive We explore the investor case for growth companies

Snapshot

  • First-in-person trial underway for Clevegen cancer treatment
  • Patients dosed showed a rise in natural killer cells and T-Cells
  • Patient’s tumour shrank after treatment
  • Clevegen may be able to reactivate T-Cells in cancer sufferers